KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
Pharmacology, Toxicology and Pharmaceutical Science
2
17%
Medicine and Dentistry
2
17%
Unknown
8
67%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2023.
All research outputs
#1,593,229
of 26,876,183 outputs
Outputs from Journal of Clinical Oncology
#3,926
of 23,248 outputs
Outputs of similar age
#31,284
of 402,188 outputs
Outputs of similar age from Journal of Clinical Oncology
#122
of 823 outputs
Altmetric has tracked 26,876,183 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 23,248 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.4. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 402,188 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 823 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.
